Navigation Links
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
Date:9/22/2008

LA JOLLA, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing non-invasive, topically administered medications, today announced it has enrolled its first patient in the Phase 3 registration trial for Ketotransdel(TM). Ketotransdel(TM), a novel analgesic and anti-inflammatory topical cream, contains 10% ketoprofen (a non-steroidal anti-inflammatory drug, "NSAID"), and is intended for use in the treatment of acute pain from musculoskeletal conditions.

The Ketotransdel(TM) Phase 3 registration study entitled: "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel(TM) in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury," will be conducted at approximately 25 to 35 sites in the United States and potentially in Canada. The Company expects to enroll approximately 350 patients of which 50% will be provided Ketotransdel(TM) and 50% a placebo vehicle. The Phase 3 study currently has three sites that are actively screening for patients. It is expected that the majority of the sites will be activated during October and November. The Company expects to report top-line results in the second half of 2009.

In the Phase 3 study, the primary efficacy endpoint will be the difference in the change of baseline pain between Ketotransdel(TM) and placebo at Day 3. This endpoint is measured by using the Visual Analogue Scale (VAS), a validated and widely used scale for recording pain which 0 indicates "no pain" and 100 indicates "the worst imaginable pain." The secondary endpoints will include safety assessments and other efficacy parameters measured by VAS at Day 3 and Day 7. In addition to evaluating for efficacy and safety over the one week period, the study will also assess safety at one week post-treatment.

"We are excited about reaching
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
7. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... June 2, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... presentation at the Jefferies 2011 Global Healthcare Conference in New ... Time. Bruce Cozadd, the company,s chairman and chief executive officer, ... live webcast of presentation may be accessed from the Investors ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Bisaro, Watson,s President and Chief Executive Officer, will provide ... the 2011 Goldman Sachs 32nd Annual Global Healthcare Conference ... at the Terranea Resort in Rancho Palos Verdes, California. ...
Cached Medicine Technology:
(Date:7/30/2014)... Ramon, CA (PRWEB) July 30, 2014 ... the ancient redwood forests of the Pomo Indians located ... The Pomo called the river Shabaikai, meaning ‘crooked snake’. ... its labor strife and the violence of prohibition and ... Club at Russian River. Here, the most powerful men ...
(Date:7/30/2014)... 2014 With the recent May 21st opening ... Ground Zero Museum Workshop in the Meatpacking District has been ... Museum Workshop's Carole Barnes, "We have had to re-write the ... travel sites who sell us so tourists don't confuse the ... to what we do and what the new Museum does ...
(Date:7/30/2014)... for Vedic Studies (WAVES) conference is coming to Fairfield, ... 31 through Sunday, August 3. To watch the main ... the first time such a large and diverse group ... to explore the relevance of ancient Vedic knowledge in ... states of consciousness, and reflections on the various Vedic ...
(Date:7/30/2014)... 2014 Today, Gen. Arthur T. Dean, ... America (CADCA) , the nation’s leading substance abuse prevention ... New York Times Editorial Board’s call for ... , “CADCA is disappointed in the New York ... national marijuana legalization. The move is shortsighted and completely ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Clues to whether a ... simple blood test, a new study suggests. Chemical changes ... hormones may help spur suicidal thoughts and behaviors, the study,s ... help alert doctors to a patient,s risk for suicide, they ... but we have been stymied in our prevention efforts because ...
Breaking Medicine News(10 mins):Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3
... ... Circulation Heart Failure, a journal of the American Heart Association, ... is more accurate than the current listing criteria for heart transplantation ... intervention. The study conclusions reinforce the science behind the Shape-HFTM Cardiopulmonary ...
... ... based company, providing residential and commercial pest control services, is proud to announce the launch ... ... this week, Clark Pest Control’s 2010 television advertising campaign will air on stations across California ...
... disabilities related to mobility increased significantly from 1997 to 2007, ... among Americans ages 65 and over, according to a new ... Researchers found a rise in the proportion of Americans ... need for help in daily personal care activities such as ...
... drink, study finds , MONDAY, April 5 (HealthDay News) -- ... imbibe a bit too much themselves. , And the same ... relatives are more likely not to consume alcohol themselves, a ... behavior more than would be predicted by chance alone," said ...
... still needs testing , MONDAY, April 5 (HealthDay News) ... have found that tick-borne transmission might be preventable by ... infection. , Though to date the strategy has been ... toward development of a vaccine that reduces the risk ...
... Addiction rehabilitation center ... available at YouTube , ... TX (Vocus) April 5, 2010 -- With the numerous addiction rehabilitation programs available today, many ... program offering is best suited for their individual needs. In a new video available to ...
Cached Medicine News:Health News:Study Published by Circulation Heart Failure Reinforces Science Behind Shape-HF Cardiopulmonary Exercise Testing Device 2Health News:Study Published by Circulation Heart Failure Reinforces Science Behind Shape-HF Cardiopulmonary Exercise Testing Device 3Health News:Study Published by Circulation Heart Failure Reinforces Science Behind Shape-HF Cardiopulmonary Exercise Testing Device 4Health News:Marysville Girl Stars in TV Advertising Campaign 2Health News:Middle-aged Americans reporting more mobility related disabilities, study finds 2Health News:Middle-aged Americans reporting more mobility related disabilities, study finds 3Health News:Your Social Network Affects Your Drinking Habits 2Health News:Your Social Network Affects Your Drinking Habits 3Health News:Genetic Engineering Raises Hope for Lyme Disease Vaccine 2Health News:Genetic Engineering Raises Hope for Lyme Disease Vaccine 3Health News:Drug Rehab Treatment Center Explains Rehabilitation Program Using YouTube 2
HRT II is the smallest scanning laser ever, light, portable and ready for telemedicine....
...
... Horizon Phacoemulsification System is a ... Lightweight and portable, it offers ... a small console. It also ... perform anterior segment surgery. These ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Medicine Products: